Tag: ESC
ESC: Merck’s Steglatro shows limited promise with heart failure hospitalization data
Late to the party against its SGLT2 diabetes rivals, Merck & Co.'s Steglatro has also tracked way behind in the class' growing presence in...
ESC: Novartis’ Entresto racks up a heart failure study win—but it’s...
As the bestselling drug in the heart failure space, Novartis' Entresto suffered a stinging setback last year in a novel indication—but there were some...
ESC: Pfizer, BMS’ Eliquis tops Xarelto, vitamin K drugs for site-specific...
Pfizer and Bristol Myers Squibb's anticoagulant superstar Eliquis has raced out to blockbuster sales in recent years and a big-time lead over its its...